A61P 25/24
Antidepressants
A61P25/24 (Antidepressants) appears on 11,686 US grants and 16,651 published applications in this corpus.
Search patents in A61P- Granted patents
- 11,686
- Published applications
- 16,651
- Assignees
- 3,635
- Inventors
- 23,392
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 22 | 0 |
| 1977 | 13 | 0 |
| 1978 | 22 | 0 |
| 1979 | 23 | 0 |
| 1980 | 29 | 0 |
| 1981 | 32 | 0 |
| 1982 | 31 | 0 |
| 1983 | 19 | 0 |
| 1984 | 22 | 0 |
| 1985 | 41 | 0 |
| 1986 | 40 | 0 |
| 1987 | 37 | 0 |
| 1988 | 46 | 0 |
| 1989 | 62 | 0 |
| 1990 | 60 | 0 |
| 1991 | 54 | 0 |
| 1992 | 52 | 0 |
| 1993 | 67 | 0 |
| 1994 | 66 | 0 |
| 1995 | 68 | 0 |
| 1996 | 92 | 0 |
| 1997 | 157 | 0 |
| 1998 | 121 | 0 |
| 1999 | 131 | 0 |
| 2000 | 175 | 0 |
| 2001 | 219 | 59 |
| 2002 | 327 | 411 |
| 2003 | 308 | 647 |
| 2004 | 262 | 858 |
| 2005 | 277 | 796 |
| 2006 | 398 | 838 |
| 2007 | 388 | 905 |
| 2008 | 446 | 999 |
| 2009 | 482 | 1102 |
| 2010 | 602 | 1314 |
| 2011 | 586 | 1058 |
| 2012 | 719 | 949 |
| 2013 | 743 | 719 |
| 2014 | 665 | 669 |
| 2015 | 544 | 643 |
| 2016 | 470 | 563 |
| 2017 | 493 | 564 |
| 2018 | 408 | 504 |
| 2019 | 333 | 476 |
| 2020 | 307 | 454 |
| 2021 | 281 | 410 |
| 2022 | 241 | 379 |
| 2023 | 187 | 374 |
| 2024 | 211 | 389 |
| 2025 | 202 | 352 |
| 2026 | 105 | 219 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Method of treating and ameliorating depression6 Oct 2026US 12,751,935 B2The United States Government as represented by the Department of Veterans Affairs
- Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin6 Oct 2026US 12,751,960 B2Compass Pathfinder Limited
- Compounds for treating CNS- and neurodegenerative diseases29 Sep 2026US 12,746,224 B2ETH Zurich
- EAAT2 activators and methods of using thereof29 Sep 2026US 12,747,227 B2Ohio State Innovation Foundation
- Heterocyclic flavone derivatives, compositions, and methods related thereto15 Sep 2026US 12,735,426 B2Emory University
- Composition for removing and inhibiting senescent cells, and uses thereof8 Oct 2026US 2026/0306460 A1Lifeceutix Co., Ltd.
- Combination therapy for treatment of depression8 Oct 2026US 2026/0306839 A1Flow Neuroscience, Inc.
- Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders8 Oct 2026US 2026/0308198 A1Sage Therapeutics, Inc.
- Ketamine for the treatment of menstrually related symptoms1 Oct 2026US 2026/0294843 A1
- Beta-hydroxybutyrate for the dietary management of depression1 Oct 2026US 2026/0294854 A1Laureate Institute For Brain Research
Most cited
By later US patents
- Process for preparing diaminophenothiazinium compounds687US 8,765,942 B2Provence Technologies · 2014
- Dual variable domain immunoglobulin and uses thereof391US 7,612,181 B2Abbott Laboratories · 2009
- Controlled release bases for pharmaceuticals383US 4,861,598 AEuroceltique, S.A. · 1989
- Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents342US 6,309,663 B1Lipocine Inc. · 2001
- Pharmaceutical compositions containing an omega-3 fatty acid oil306US 6,284,268 B1Cyclosporine Therapeutics Limited · 2001